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Abstract
Background: There are sparse data on whether non-pharmaceutical interventions can reduce the spread of influenza. We
implemented a study of the feasibility and efficacy of face masks and hand hygiene to reduce influenza transmission among
Hong Kong household members.
Methodology/Principal Findings: We conducted a cluster randomized controlled trial of households (composed of at least
3 members) where an index subject presented with influenza-like-illness of ,48 hours duration. After influenza was
confirmed in an index case by the QuickVue Influenza A+B rapid test, the household of the index subject was randomized to
1) control or 2) surgical face masks or 3) hand hygiene. Households were visited within 36 hours, and 3, 6 and 9 days later.
Nose and throat swabs were collected from index subjects and all household contacts at each home visit and tested by viral
culture. The primary outcome measure was laboratory culture confirmed influenza in a household contact; the secondary
outcome was clinically diagnosed influenza (by self-reported symptoms). We randomized 198 households and completed
follow up home visits in 128; the index cases in 122 of those households had laboratory-confirmed influenza. There were 21
household contacts with laboratory confirmed influenza corresponding to a secondary attack ratio of 6%. Clinical secondary
attack ratios varied from 5% to 18% depending on case definitions. The laboratory-based or clinical secondary attack ratios
did not significantly differ across the intervention arms. Adherence to interventions was variable.
Conclusions/Significance: The secondary attack ratios were lower than anticipated, and lower than reported in other
countries, perhaps due to differing patterns of susceptibility, lack of significant antigenic drift in circulating influenza virus
strains recently, and/or issues related to the symptomatic recruitment design. Lessons learnt from this pilot have informed
changes for the main study in 2008.
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Introduction
The specter of an influenza pandemic continues to threaten,
with annual outbreaks of highly-pathogenic H5N1 in birds [1] and
continued sporadic human H5N1 cases and clusters [2] with some
reports that suggested limited, non sustained human-to-human
transmission of H5N1 viruses [3,4]. If a pandemic virus strain were
to emerge, pre-pandemic vaccines would be available to some
populations although of unknown efficacy, but development and
distribution of initial doses of influenza vaccine specifically made
against the pandemic strain would not be available for at least 4–6
months [5]. Influenza antiviral medications would likely be in
short supply in many regions, particularly in developing countries,
and might have modest effectiveness against the pandemic strain,
PLoS ONE | www.plosone.org 1 May 2008 | Volume 3 | Issue 5 | e2101because of the emergence of antiviral resistance or other reasons
[6]. Furthermore, few of these pharmaceutical measures can be
applied at pandemic scale. Only non-pharmaceutical interventions
[7–12] including use of face masks, improved hand hygiene, cough
etiquette, social distancing measures, and travel restrictions would
be available to the majority of the world’s population. Interpan-
demic influenza is associated with thousands of deaths every year
in Hong Kong [13] and likely hundreds of thousands worldwide
every year [14,15], therefore simple personal protective measures
could be beneficial during annual epidemics if found to be effective
in reducing transmission, and as an adjunct to influenza
vaccination.
We implemented a prospective cluster-randomized trial [16] to
test whether two such non-pharmaceutical interventions can
reduce transmission of interpandemic influenza in households.
Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Protocol S1 and
Checklist S1.
Recruitment and follow-up of participants
From 30 first-contact outpatient clinics in both the private and
public sectors across Hong Kong, we enrolled 944 Hong Kong
residents aged at least 2 years, reporting at least two symptoms of
influenza-like-illness (ILI) (such as fever $38uC, cough, sore
throat, coryza, headache, malaise, chills, fatigue, etc.), and living in
a household with at least two other individuals none of whom had
reported ILI symptoms in the preceding 14 days. These index
subjects provided nasal and throat swab (NTS) specimens which
were combined and tested with the QuickVue Influenza A+B
rapid diagnostic test (Quidel Corp, San Diego, CA) and those
subjects with a positive result for influenza A or B were
randomized and further followed up. For participants enrolled
after June 1, 2007, those index subjects with a negative QuickVue
result but a fever $38uC were also randomized and further
followed up. Data on clinical signs and symptoms were collected
for all subjects, and an additional NTS was collected for later
confirmation of influenza infection by viral culture.
Followingrandomizationahomevisitwasscheduled(totakeplace
within 36 hours) to implement the intervention, collect baseline
demographic data and NTS from all household members aged $2
years, and to provide and describe proper use of a free tympanic
thermometer and the daily symptom record sheets. During the 9
days following the initial home visit, all household members were
asked to keep symptom diaries, and three further home visits were
scheduled at 3, 6 and 9 days after the baseline household visit to
monitor adherence to interventions and to collect further NTS from
allhouseholdmembersaged$2years.Atthefinal(day9)homevisit,
the study nurse collected the symptom diaries and evaluated
adherence to interventions by interview and by counting the
number of surgical masks remaining or weighing the amount of soap
and alcohol left in bottles and dispensers.
Ethics
All subjects aged 18 years and older gave written informed
consent. Proxy written consent from parents or legal guardians
was obtained for subjects aged 17 years and younger, with
additional written assent from those aged 8 to 17 years. The study
protocol was approved by the Institutional Review Board of the
University of Hong Kong/Hospital Authority Hong Kong West
Cluster and was conducted in compliance with the Declaration of
Helsinki [17].
Interventions
Our study compared three interventions. In the control arm,
households received education about the importance of a healthy
diet and lifestyle, both in terms of illness prevention (for household
contacts) and symptom alleviation (for the index). Households in
the face mask arm received the control intervention plus education
about the potential efficacy of masks in reducing disease spread to
household contacts if all parties wear masks, distribution of a box
of 50 surgical masks (Tecnol – The Lite One, Kimberly Clark,
Roswell, GA) for each household member (or a box of 75
paediatric masks for children aged 3–7 years), and demonstration
of proper face-mask wearing and hygienic disposal. Index subjects
and all household contacts were taught to wear masks as often as
possible at home (except when eating or sleeping) and also when
the index was with the household members outside of the
household. Households in the hand hygiene group received the
control intervention plus education about the potential efficacy of
proper hand hygiene in reducing transmission, distribution of an
automatic alcohol hand sanitizer (WHO recommended formula-
tion II, liquid content with 75% isopropyl alcohol, Vickmans Labs
Ltd., Hong Kong), liquid hand soap (Avalon organics glycerin
hand soap, Petaluma, CA), individual small (125 ml) bottles of
alcohol hand gel (Gellygen gel with 70% ethyl alcohol, Brymore
SA, Italy), and demonstration of proper hand washing and hand
antisepsis [18]. All household members including the index subject
were taught to use the liquid soap in place of their regular soap
after every washroom visit and in general when their hands were
soiled or after sneezing or coughing, while they should use the
alcohol hand sanitizer or hand rub when first returning home and
immediately after touching any potentially contaminated surfaces.
At the final home visit, households were reimbursed for their
participation time with a supermarket voucher worth approxi-
mately US$20.
Objectives
The overall objective of the study was to quantify the efficacy of
face masks and/or hand hygiene in reducing transmission of
influenza to household contacts at the individual level. Specific
objectives of this pilot study were to confirm the feasibility of the
study design including the practicability of patient recruitment,
randomization and follow-up, the appropriateness of the estimated
sample size for a subsequent larger trial in terms of characteristics
of local circulating influenza viruses and potential effect sizes, the
applicability of the interventions and individual adherence with
the interventions.
Outcomes
The primary outcome measure was the secondary attack ratio
(SAR) at the individual level i.e. the proportion of household
contacts of an index case who subsequently became ill with
influenza. We evaluated the SAR using a laboratory definition (at
least one follow-up NTS positive for influenza by viral culture or
PCR) as the primary analysis, and three different clinical
definitions of influenza as secondary analyses. The first definition
of clinical influenza was fever $38uC or at least two of the
following symptoms: headache, coryza, sore throat, aches or pains
in muscles or joints, cough, or fatigue. The second definition was
at least two of the following signs and symptoms: fever $37.8uC,
cough, headache, sore throat, aches or pains in muscles or joints
[19]. The third definition was the standard WHO/CDC
influenza-like illness definition: fever $37.8uC plus cough or sore
throat [20]. A secondary outcome measure was the secondary
attack rate (SAR) at the household (cluster) level i.e. the proportion
of households with one or more secondary case.
Effectiveness of NPIs for Flu
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We estimated that we would require 51 households (average size
3.8) in the control arm to allow determination of a secondary
attack ratio of approximately 24% [21] to within +/27%.
Allowing for potential dropout, we therefore planned to recruit
at least 60 households in the control arm, and a further 25–30
households to each of the face mask and hand hygiene arms to
evaluate the feasibility of the interventions and allow a preliminary
albeit imprecise estimate of efficacy. This pilot study was not
powered to detect small or moderate efficacies of the interventions
with statistical significance. We did not specify any early stopping
rules or interim analyses.
Randomization
Randomization lists were prepared by a biostatistician (B.J.C.).
Eligible study participants were randomly allocated to three
groups. The first 100 households were randomized in the ratio
2:1:1 and subsequent households were randomized in the ratio
8:1:1 using a random number generator (R software). The
rationale for changing the randomization ratio was to allow us
to gather maximum information about the natural characteristics
of influenza transmission in households in the absence of control
measures, after evaluating the feasibility of each of the interven-
tions in at least 25 households. Interventions were assigned to
households by the study manager (R.O.P.F.) based on the
randomization sequence. The allocation to specific intervention
arms was concealed to recruiting doctors/clinics throughout.
Blinding
Participants and those administering interventions were not
blinded to the interventions, but participants were not informed of
the specific nature of the other interventions applied to other
participating households.
Laboratory methods
Nasal swabs were collected by inserting and rotating a sterile
swab (Collection swab; EUROTUBO, Madrid, Spain) into the
anterior nares. Throat swabs were collected by rubbing a second
sterile swab against the tonsillar fossa. Both swabs were snapped
off into a tube containing viral transport medium (5% bovine
serum albumin in Earle’s balanced salt solution with antibiotic). At
recruitment, additional nose and throat swabs were collected using
sterile foam swabs and then combined and tested by the QuickVue
Influenza A+B rapid diagnostic test.
Specimens collected from index subjects at recruitment were
stored in a 2–8uC refrigerator (overnight, if required). Specimens
collected during home visits were stored in a cool box with at least
two icepacks immediately after collection. Before the end of the
day of a home visit, study nurses took samples to the nearest
collection point for storage in a 2–8uC refrigerator (overnight, if
required) or directly to the central testing laboratory. Samples
stored at 2–8uC were delivered to the central testing laboratory by
courier in cool boxes en route. Samples were eluted and
cryopreserved at 270uC immediately after receipt.
All clinical specimens were cultured on Madin-Darby canine
kidney cells with exogenous trypsin (2 ug/ml) added. In
households which were successfully followed up with home visits,
the clinical specimens collected from index subjects at the
recruiting clinic and during the first home visit were additionally
tested by reverse transcription polymerase chain reaction (RT-
PCR) for influenza A and B viruses if both specimens were
negative by viral culture. For household contacts who reported
symptoms during the follow-up but whose corresponding clinical
specimens (collected within +/22 days of self-reported fever or
other respiratory symptoms) were negative by viral culture, those
specimens were additionally tested for influenza A and B by RT-
PCR. Additional technical details of the laboratory procedures
employed in viral culture and RT-PCR testing are given in Text
S1.
Statistical methods
To evaluate the SAR and to compare between groups we used
exact binomial 95% confidence intervals, and x
2 tests and
multivariable logistic regression models adjusting for potential
within-household correlation [22,23], with a 5% type I error rate.
We estimated the intra-cluster correlation coefficient from the
mean squared errors in the SAR between and within households
[22]. All analyses were by intention-to-treat. We evaluated the
three definitions of clinical influenza described above using
receiver operating characteristic (ROC) analysis to determine the
clinical definition that corresponds most closely to the laboratory
outcome measure [24]. All analyses were conducted in R version
2.4.1 [25].
Results
Nine hundred and forty-four subjects were initially recruited to
the study between February 24 and September 14, 2007. Figure 1
shows the progress of subjects and household contacts through the
study. Overall, and in each intervention arm, the median
household size was 4. Both the recruitment rate of subjects and
the percentage of positive rapid influenza test results among
recruited subjects increased in line with other measures of
influenza activity including sentinel outpatient visits and labora-
tory isolations in mainly inpatient specimens during the periods of
peak influenza activity in February and June (Figure S1). Of the
944 recruited subjects, 198 met the criteria for randomization and
further follow-up. In a protocol deviation we randomized 9
subjects who had symptoms for (slightly) more than 48 hours;
these 9 subjects were retained in the analyses.
Baseline data
Characteristics of the 198 subjects are shown in Table 1
according to intervention arm. In general the groups were well-
matched. After randomization 70 (35%) of the households
declined any home visits or could not be contacted after numerous
repeated attempts. Proportionally more of these dropouts were in
households where the index was a young adult, whereas there were
few dropouts when the index subject was a child. Dropout was
higher in households of index subjects who had a negative result
on the rapid influenza test (25/44, 57%) compared to those who
had a positive result (45/154, 29%).
We implemented the interventions in the remaining 128
households, and 127 (99%) were successfully followed for all four
home visits; one household completed three home visits. (Table 1)
The median household sizes were 4 in all intervention arms. We
were typically able to apply the intervention within 1–2 days of
symptom onset in the index case (Figure 2). Delays between
symptom onset and intervention did not significantly differ
between study arms (data not shown).
Numbers analyzed
Influenza could not be confirmed by viral culture or RT-PCR in
the index subjects in 6 of the 128 households; therefore we only
retained 122 households for analysis of crude SARs. Five
household contacts had missing data on age, and these were
further excluded for the multivariable regression analyses.
Effectiveness of NPIs for Flu
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The overall laboratory-confirmed SAR was 6.0% (95%
confidence interval 3.8%–9.0%) while the clinical SARs were
18%, 11% and 5% according to the three alternative definitions,
respectively, with little difference between intervention arms
(Table 2). The within-household correlation was 0.18 for the
laboratory-confirmed SAR and varied from 20.05 to 0.01 for the
various clinical definitions of influenza; chi-squared tests for
differences in SARs between intervention arms were adjusted for
these correlations (Table 2). The SARs were similar when stratified
by the delay between onset of symptoms in the index case and
application of the intervention (Table 2). Overall, 17/122 (14%)
households had one or more laboratory-confirmed secondary case,
while 44 (36%), 29 (24%) and 14 (11%) had one or more clinical
secondary cases according to the three definitions above,
respectively. SARs were similar when stratifying by influenza A
or B infection in the index case (data not shown).
Table 3 shows the odds ratios of secondary infection in a
household contact by intervention arm, adjusted for age, sex,
influenza vaccination history and the age and sex of the
corresponding index subject. Results were similar when stratified
by the delay between symptom onset and application of the
intervention (data not shown).
Ancillary analyses
A total of 24 index subjects were prescribed antivirals: 12
oseltamivir and 12 amantadine. By excluding these 24 households,
the overall laboratory and clinical secondary attack ratios
increased to 6.4% and 20%, 12% and 5% respectively, while
the adjusted odds ratios of the intervention effects were similar
(data not shown). Only three laboratory-confirmed secondary
cases (4.5%) were observed in the 67 household contacts of the 24
index cases prescribed antivirals.
The 21 laboratory-confirmed secondary cases recorded a
variety of clinical symptoms and 4 (19%) secondary cases were
asymptomatic; all 4 asymptomatic cases were confirmed by viral
culture. Of the three case definitions of clinical influenza, the
second definition (based on [19]) had slightly higher discriminatory
ability, with area under ROC curve 0.74, compared to the gold
standard of laboratory outcome, whereas our original per protocol
definition and the CDC definition had lower areas under the curve
since the former was less specific while the latter was more specific
but much less sensitive compared to laboratory-confirmed
influenza (Appendix Table S1).
In terms of adherence, 45% (21%) of index subjects
(household contacts) in the face mask arm reported wearing a
mask often or always during the follow-up period, compared to
30% (1%) and 28% (4%) in the control and hand hygiene arms,
respectively. The higher reported compliance in index subjects in
the face mask group compared to household contacts was
validated when at the final home visits the index subjects had
used a median of 12 masks (inter-quartile range, IQR: 6, 18)
whereas household contacts had only used a median of 6 (IQR:
1, 20); these include the mask worn and then disposed of by each
individual as part of the demonstration and teaching during the
initial home visit. A total of 63% (41%) of index subjects
Figure 1. Flow of subjects through the study.
doi:10.1371/journal.pone.0002101.g001
Effectiveness of NPIs for Flu
PLoS ONE | www.plosone.org 4 May 2008 | Volume 3 | Issue 5 | e2101(household contacts) in the hand hygiene arm reported washing
their hands often or always after sneezing, coughing or cleaning
their nose compared to 31% (27%) and 63% (47%) in the control
and face mask arms. In the hand hygiene group, households used
a median of 56 g (IQR: 27 g, 93 g) of alcohol from the
automatic sanitizer, and a median of 88 g (IQR: 63 g, 149 g)
of liquid hand soap, while regarding the individual bottles of
alcohol hand rub index subjects used a median of 7 g (IQR: 2 g,
13 g) and household contacts used a median of 5 g (IQR: 1 g,
12 g).
Adverse events
There were no reported adverse events, including allergic
reactions to the intervention measures or other conditions
requiring medical attention.
Discussion
If an influenza pandemic emerges, the likely limited supply of
antivirals and vaccines will mean that non-pharmaceutical
interventions have a major role to play in mitigating disease
spread [11,12]. While conventional wisdom proposes that hand
hygiene [8], and perhaps surgical masks [26], could be effective
measures to reduce household transmission of influenza, all
available data have so far been derived from at best
observational settings and mostly based on anecdotal evidence
rather than controlled trials [7,8,27]. Our study is the first
reported community-based randomized trial of these interven-
tions specifically against influenza, with laboratory-confirmed
outcomes.
Strengths of our study design include the randomized allocation
of interventions, the laboratory-based outcome measures, and our
demonstrated ability to observe secondary infections with the
implied potential to detect reduction in secondary attack ratios.
Whereas the present study was not powered to assess the relative
efficacy of the interventions, it has proved successful in
demonstrating the feasibility of our study design and the local
characteristics of influenza transmission. The present findings have
facilitated the planning of a subsequent larger study, described in
more detail in Protocol S1.
Table 1. Characteristics of 198 randomized index subjects by intervention arm; the 128 index subjects successfully followed with
home visits and their 370 household contacts.
Control Face mask Hand hygiene
Index subjects
Randomized
(n=127)
Followed up
(n=74)
Randomized
(n=35)
Followed up
(n=22)
Randomized
(n=36)
Followed up
(n=32)
Age group (%)
2–15 years 48 (38%) 33 (45%) 12 (34%) 9 (41%) 13 (36%) 12 (38%)
16–30 years 23 (18%) 10 (14%) 7 (20%) 3 (14%) 7 (19%) 6 (19%)
31–50 years 32 (25%) 17 (23%) 11 (31%) 6 (27%) 10 (28%) 10 (31%)
50+ years 24 (19%) 14 (19%) 5 (14%) 4 (18%) 6 (17%) 4 (12%)
No. (%) men 60 (47%) 32 (43%) 16 (46%) 12 (55%) 14 (39%) 12 (38%)
Symptoms (%)
Cough 99 (78%) 62 (84%) 24 (69%) 13 (59%) 33 (92%) 29 (91%)
Runny nose 98 (77%) 61 (82%) 28 (80%) 16 (73%) 28 (78%) 26 (81%)
Fatigue / tiredness 96 (76%) 56 (76%) 26 (74%) 16 (73%) 29 (81%) 25 (78%)
Fever (body
temperature$38uC)
94 (74%) 54 (73%) 25 (71%) 17 (77%) 29 (81%) 27 (84%)
Headache 80 (63%) 40 (54%) 29 (83%) 18 (82%) 22 (61%) 19 (59%)
Sore throat 69 (54%) 37 (50%) 23 (66%) 13 (59%) 22 (61%) 19 (59%)
Aches / pains in muscles or
joints
62 (49%) 34 (46%) 18 (51%) 9 (41%) 18 (50%) 16 (50%)
Onset to randomization interval (%)
0–24 hours 86 (68%) 48 (65%) 21 (60%) 14 (64%) 25 (69%) 22 (69%)
24–48 hours 35 (28%) 22 (30%) 12 (34%) 8 (36%) 7 (19%) 7 (22%)
48+ hours 5 (4%) 4 (5%) 1 (3%) 0 (0%) 3 (8%) 3 (9%)
Household contacts (n=213) (n=65) (n=92)
Age group (%)
0–15 years – – 32 (15%) – – 11 (17%) – – 14 (15%)
16–30 years – – 43 (20%) – – 13 (20%) – – 17 (18%)
31–50 years – – 92 (43%) – – 28 (43%) – – 35 (38%)
50+ years – – 43 (20%) – – 12 (18%) – – 25 (27%)
No. (%) men – – 83 (39%) – – 26 (40%) – – 37 (40%)
Influenza vaccination in the
previous 12 months
– – 29 (14%) – – 3 (1%) – – 12 (6%)
doi:10.1371/journal.pone.0002101.t001
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household transmission, our study was underpowered. Neverthe-
less, our point estimates are close to null, strongly suggesting true
equipoise until a definitive randomized trial with sufficient power
(i.e. a much larger sample size) rigorously tests the relative efficacy
of these interventions. A larger study will also allow us to explore
in more detail the transmission dynamics of influenza in
households including finer age stratifications and transmission
within and between different age groups, which was not possible in
the current study.
We observed generally low adherence to interventions. More
than one in four household contacts in the face mask group did not
wear a surgical mask at all during the follow-up period. Adherence
to the face mask intervention was higher in the index subjects,
likely due to their intention to reduce the probability of infecting
other household members and possibly because of the recent
memory of SARS in 2003, during which the majority (76%) of the
general public reported that they wore face masks in public, and
most engaged in numerous protective practices [28,29]. However
more than one in four index cases in the control and hand hygiene
intervention arms reported wearing masks at home of their own
accord, thereby contaminating this intervention.
While self-reported hand-hygiene practices were similar across
the three groups, we note that contamination of this intervention
may be lower firstly because the control and face mask group did
not receive the education component on proper hand hygiene,
secondly because those groups did not receive the alcohol sanitizer
and hand rub. Overall, adherence to the hand hygiene
intervention in terms of soap and alcohol use appeared low when
benchmarked against rates recommended in health care settings.
However we note that a previous randomized community study
found that 38% of households used more than 57 g of alcohol
hand sanitizer during a 2-week period [30], whereas more than
50% of the households in our study used more than 56 g in 10
days.
Overall, the SAR was lower than we had expected. Only 6%
of household contacts developed laboratory-confirmed influenza,
whereas 5%–18% of contacts developed clinical influenza,
depending on case definitions. This is in contrast to previous
studies in France [21], Seattle [31] and other places [19], where
SARs were approximately 25% (laboratory-confirmed influenza
in the latter two studies). There could be a number of reasons for
this. First, there has not been significant antigenic drift in the
predominant circulating strains of influenza viruses in recent
years, potentially resulting in higher levels of pre-existing
immunity among our study population. Secondly, our inclusion
criteria specified that an index subject should be the only
member of their household to be suffering from ILI, and no
other household contacts should have experienced ILI in the past
14 days, to ensure that the index is a true index within the
household. However, the latter condition may have biased our
recruitment towards households where some members were
already immune from infection, since among households where
all contacts were susceptible there might be a greater possibility
of secondary cases being observed prior to the index case
presenting to their primary care provider 1–2 days after
symptom onset (Figure 2a). However the French study used
similar inclusion criteria and found a much higher SAR [21].
Antiviral prescriptions for index subjects followed with home
visits appears to affect transmission as would be expected [19],
where there was a relative reduction in the SAR of approxi-
mately 30% albeit based on a limited sample size. Vaccination of
household contacts might also have reduced the risk of secondary
infection (Table 3). Finally, environmental or behavioral
differences could lead to differing secondary transmission rates
in our study, for example differences in use of air conditioning,
high background use of face masks, or differences in the amount
of time spent with family members at home. We did not collect
the relevant data in the present study however; future studies
should consider these externalities. Results from other settings
with a similar design would be helpful in assessing, at least
qualitatively, these respective effects.
The variability in clinical SARs depending on the choice of
case definition has been noted in previous studies [21,32,33].
Influenza infection is associated with a wide spectrum of
symptoms and severities, and in our study 4 (19%) of the 21
laboratory-confirmed secondary cases were asymptomatic. On
the other hand, only 10 (48%) of laboratory-confirmed
secondary cases reported fever $38uC. With such a range of
symptoms caused by influenza, and when infections with other
circulating upper respiratory viruses cause similar symptoms,
collectively referred to as influenza-like-illnesses, it is difficult to
find a single case definition which is highly sensitive and also
highly specific for influenza virus. With a small sample size it is
not possible here to derive clinical prediction rules [33–38],
however we compared three alternative case definitions and
Figure 2. Delays between index case symptom onset, random-
ization, and intervention in 128 households. Time intervals a)
from symptom onset in the index subject to randomization; b) from
randomization to application of the intervention; c) from symptom
onset to application of the intervention.
doi:10.1371/journal.pone.0002101.g002
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curve) was at least two of the following signs and symptoms: fever
$37.8uC, cough, headache, sore throat, aches or pains in
muscles or joints (Appendix Table S1). While the clinical SARs
rely on self-reported symptoms, the diaries were checked for
completeness and accuracy by trained nurses during home visits
every 3 days. The proportion of asymptomatic infection in our
study was lower than might have been expected (i.e. closer to
50%) based on earlier studies with paired serology [31], perhaps
suggesting that we might have missed some infections when
assessing the secondary outcomes of clinical influenza. The
corollary is that the true secondary infection rate might well have
been higher than estimated (and estimable) by our SARs.
The dropout was higher than anticipated; all subjects were
advised of the study requirements and gave informed consent
before being recruited into the study (and tested by rapid
influenza test without charge), but 35% of randomized subjects/
households refused to allow any home visits. These decisions
were independent of the allocated intervention, since the
interventions were only revealed during the first home visit.
Dropout was higher among the group randomized with a
negative result on the rapid diagnostic test (after June 1, 2008),
perhaps because subjects interpreted their negative result as
indicating they did not have influenza thus did not require
follow-up. A negative rapid test result does not rule out influenza
virus infection [39], and we chose to randomize such subjects to
allow wider generalizability in terms of including index subjects
with a likely greater range of influenza viral shedding profiles
albeit with the limitation that some index subjects might have
been infected with a different pathogen; in the latter case those
households would be unnecessarily followed up since only
households with index subjects with confirmed influenza (by
viral culture or RT-PCR) were included in the final analyses. We
found that dropout rates were lower when the index subject
wasaged 15 years or younger (Table 1) perhaps because
the accompanying parent would have also given immediate
consent.
Other limitations of our study design include the potential bias
from recruiting symptomatic subjects, resulting in three distinct
effects. First, the use of a point-of-care test to detect influenza
virus infection, ensuring that the majority of followed-up
households will include an index case with laboratory-confirmed
influenza (98% in our study), could also preferentially detect
those potential recruits with higher viral shedding and subjects
with lower levels of viral shedding would be more likely to
receive a false negative rapid test results, and not be recruited.
However we note that statistical power would be generally
increased if index cases were more infectious since we might
therefore observe more secondary transmission; the limitation
here relates more to generalizability. Secondly, our design results
in an unavoidable delay between onset of symptoms in the index
subject and the application of the intervention (Figure 2c). If a
significant amount of influenza transmission occurred prior to
the intervention, we might have underestimated the efficacy of
the non-pharmaceutical interventions or lacked the statistical
power to find significant differences. In our analyses we
investigated the SARs for those households where the interven-
tion was applied within 36 hours of symptom onset but there was
Table 2. Secondary attack ratios of laboratory-confirmed influenza and clinical influenza in the contacts of 122 analyzed
households, by intervention arm.
Interval between symptom onset and
intervention
Secondary attack ratio (95% CI
*)
p-value
{
Control Face mask Hand hygiene
(n=205) (n=61) (n=84)
Any Laboratory confirmed influenza 0.06 (0.03, 0.10) 0.07 (0.02, 0.16) 0.06 (0.02, 0.13) 0.99
Clinical influenza definition 1
{ 0.18 (0.13, 0.24) 0.18 (0.09, 0.30) 0.18 (0.10, 0.28) 1.00
Clinical influenza definition 2
{ 0.11 (0.07, 0.16) 0.10 (0.04, 0.20) 0.11 (0.05, 0.19) 0.97
Clinical influenza definition 3
{ 0.04 (0.02, 0.08) 0.08 (0.03, 0.18) 0.04 (0.01, 0.10) 0.52
(n=110) (n=32) (n=41)
#36 hours Laboratory confirmed influenza 0.06 (0.03, 0.13) 0.12 (0.04, 0.29) 0.10 (0.03, 0.23) 0.69
Clinical influenza definition 1{ 0.17 (0.11, 0.26) 0.25 (0.11, 0.43) 0.17 (0.07, 0.32) 0.76
Clinical influenza definition 2{ 0.11 (0.06, 0.18) 0.09 (0.02, 0.25) 0.10 (0.03, 0.23) 0.98
Clinical influenza definition 3{ 0.04 (0.01, 0.09) 0.09 (0.02, 0.25) 0.05 (0.01, 0.17) 0.44
(n=95) (n=29) (n=43)
.36 hours Laboratory confirmed influenza 0.05 (0.02, 0.12) 0.00 (0.00, 0.12) 0.01 (0.00, 0.12) 0.30
Clinical influenza definition 1{ 0.19 (0.12, 0.28) 0.10 (0.02, 0.27) 0.19 (0.08, 0.33) 0.71
Clinical influenza definition 2{ 0.12 (0.06, 0.20) 0.10 (0.02, 0.27) 0.12 (0.04, 0.25) 0.99
Clinical influenza definition 3{ 0.05 (0.02, 0.12) 0.07 (0.01, 0.23) 0.02 (0.00, 0.12) 0.79
*Confidence intervals were calculated by the exact binomial method, not accounting for within-household correlation, and the resulting intervals may therefore slightly
underestimate the uncertainty about the SARs.
{By Pearson chi-square test adjusted for within-household correlation.
{Clinical influenza definition 1 is fever$38uC or at least 2 of headache, runny nose, sore throat, aches or pains in muscles or joints, cough, or fatigue. Clinical influenza
definition 2 is at least 2 of fever$37.8uC, cough, headache, sore throat, aches or pains in muscles or joints. Clinical influenza definition 3 is the standard CDC
classification of fever$37.8uC plus cough or sore throat.
doi:10.1371/journal.pone.0002101.t002
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is the potential for recruited households to be biased towards
including household contacts with pre-existing immunity, as
discussed above. An alternative approach would have been to
randomize a much larger cohort of initially uninfected
households, who were then followed throughout an influenza
season. However such a longitudinal study would require greater
resources by several orders of magnitude than the one proposed
here, due to the low attack rate of influenza.
In conclusion, there remains a serious deficit in the evidence
base of the efficacy of non-pharmaceutical interventions. The US
Centers for Disease Control and Prevention have awarded grants
to study non pharmaceutical interventions in community settings
[40], including this study. Other funded study designs include
symptom-based recruitment (as in our study) and longitudinal
studies of initially uninfected cohorts, in children and adults and in
various settings including households, schools and student halls of
residences. We eagerly anticipate that conclusive evidence will
become available as these studies proceed in the coming months,
finally allowing empirically-driven pandemic planning.
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Table 3. Factors affecting the laboratory-confirmed influenza and clinical influenza secondary attack ratios in the 350 household
contacts.
n
Laboratory-confirmed
influenza Clinical influenza*
Definition 1 Definition 2 Definition 3
OR
{ 95% CI for OR OR
{ 95% CI for OR OR
{ 95% CI for OR OR
{ 95% CI for OR
Control group 202 1.00 1.00 1.00 1.00
Face mask group 60 1.16 (0.31, 4.34) 0.88 (0.34, 2.27) 0.87 (0.30, 2.51) 2.00 (0.57, 7.02)
Hand hygiene group 83 1.07 (0.29, 4.00) 0.86 (0.39, 1.91) 0.88 (0.36, 2.14) 0.80 (0.22, 2.89)
Child (aged#15) 54 1.00 1.00 1.00 1.00
Adult (aged 16+) 291 1.75 (0.43, 7.16) 0.59 (0.31, 1.15) 1.40 (0.56, 3.53) 1.28 (0.36, 4.60)
Female 211 1.00 1.00 1.00 1.00
Male 134 1.10 (0.52, 2.33) 0.87 (0.51, 1.47) 0.76 (0.39, 1.48) 0.99 (0.38, 2.58)
Not vaccinated 308 1.00 1.00 1.00 1.00
Vaccinated in past 1 year 37 0.46 (0.07, 2.98) 1.42 (0.72, 2.79) 1.30 (0.55, 3.08) 0.63 (0.10, 4.07)
Child (aged#15) index 52 1.00 1.00 1.00 1.00
Adult (aged 16+) index 70 0.51 (0.18, 1.43) 0.83 (0.42, 1.66) 0.82 (0.36, 1.87) 0.55 (0.16, 1.84)
Female index 68 1.00 1.00 1.00 1.00
Male index 54 0.80 (0.30, 2.13) 0.95 (0.48, 1.88) 0.79 (0.35, 1.80) 1.44 (0.43, 4.85)
*Clinical influenza definition 1 is fever$38uC or at least 2 of headache, runny nose, sore throat, aches or pains in muscles or joints, cough, or fatigue. Clinical influenza
definition 2 is at least 2 of fever$37.8uC, cough, headache, sore throat, aches or pains in muscles or joints. Clinical influenza definition 3 is the standard CDC
classification of fever$37.8uC plus cough or sore throat.
{OR=odds ratio.
doi:10.1371/journal.pone.0002101.t003
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